Premium
Increased Plasma Transforming Growth Factor‐β1 in Migraine
Author(s) -
Ishizaki Kumiko,
Takeshima Takao,
Fukuhara Yoko,
Araki Haruko,
Nakaso Kazuhiro,
Kusumi Masayoshi,
Nakashima Kenji
Publication year - 2005
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.2005.00246.x
Subject(s) - migraine , aura , medicine , tension headache , migraine with aura , transforming growth factor , proinflammatory cytokine , anesthesia , gastroenterology , inflammation
Background and Objectives.—Migraine is characterized by the peripheral and central sensitization of pain perceptive neural systems, and neurogenic inflammation is a key step in the development of migraine headache. We focused on transforming growth factor‐β1 (TGF‐β1), which is a multifunctional proinflammatory cytokine. To address the possibility of TGF‐β1 involvement in migraine, we investigated the plasma level of TGF‐β1 in patients with migraine headache during headache‐free periods. Subjects and Methods.—Sixty‐eight subjects with migraine participated: 23 with migraine with aura (MWA) and 45 without aura (MWoA). We recruited 58 healthy subjects without headache as controls. In addition, we examined 12 subjects with episodic tension‐type headache. Platelet poor plasma (PPP) was obtained from subjects during headache free‐periods. TGF‐β1 levels in PPP were determined by enzyme‐linked immunosorbent assay. Results.—The TGF‐β1 level in PPP was 2.62*± 0.23 (mean ± SE) ng/mL in migraine, 2.08 ± 0.20 ng/mL in tension‐type headache, and 1.80 ± 0.09 ng/mL in controls ( P = .007, ANOVA; * P < .01, post hoc tests vs. the controls). Conclusion.—TGF‐β1 in PPP was significantly increased in patients with migraine during headache‐free periods. TGF‐β1 may play some role in the development of migraine headache.